检索结果-南通市图书馆

Characterization of Driving Style and the Influence of Distraction Based on Non-intrusive Driving Parameters

Journal of Mechanics Engineering and Automation 2011年第6期1卷 413-419页

作者： felipe jimenez juan jose sanchez oscar gomez University Institute for Automobile Research Technical University of Madrid Madrid 28031 Spain

It is difficult to model human behavior because of the variability in driving styles and driving skills. However, for some driver assistance systems, it is necessary to have knowledge of that behavior to discriminate potentially hazardous situations, such as distraction, fatigue or drowsiness. Many of the systems that look for driver distraction or drowsiness are based on intrusive means （analysis of the electroencephalogram--EEG） or highly sensitive to operating conditions and expensive equipment （eye movements analysis through artificial vision）. A solution that seeks to avoid the above drawbacks is the use of driving parameters This article presents the conclusions obtained after a set of driving simulator tests with professional drivers with two main objectives using driving variables such as speed profile, steering wheel angle, transversal position on the lane, safety distance, etc., that are available in a non-intrusive way：（1） To analyze the differences between the driving patterns of individual drivers; and （2） To analyze the effect of distraction and drowsiness on these parameters. Different scenarios have been designed, including sequences with distractions and situations that cause fatigue. The analysis of the results is carried out in time and frequency domains in order to identify situations of loss of attention and to study whether the evolution of the analyzed variables along the time could be considered independent of the driver.

关键词： ADAS (advanced driver assistance systems) driver behavior distraction driving simulator professional driver.

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effectiveness and safety of first-generation protease inhibitors in clinical practice:Hepatitis C virus patients with advanced fibrosis

引用

World Journal of Gastroenterology 2015年第30期21卷 9163-9174页

作者： Javier Salmeron Carmen Vinaixa Ruben Berenguer juan Manuel Pascasio juan jose sanchez Ruano Miguel angel Serra Ana Gila Moises Diago Manuel Romero-gomez jose Maria Navarro Milagros Testillano Conrado Fernandez Dolores Espinosa Isabel Carmona jose Antonio Pons Francisco Jorquera Francisco Javier Rodriguez Ramon Perez jose Luis Montero Rafael Granados Miguel Fernandez Ana Belen Martin Paloma Munoz de Rueda Rosa Quiles CIBERehd Instituto de Salud Carlos Ⅲ28029 MadridSpain Unit for Clinical Management of Digestive Diseases Complejo Hospitalario Universitario de Granada Instituto de Investigacion Biosanitaria de Granada University Hospital Politecnico La Fe Unit for Clinical Management of Digestive Diseases University Hospital Virgen Del Rocio Hospital Toledo University Clinic Hospital of Valencia University General Hospital of Valencia Unit for Clinical Management of Digestive Diseases University Hospital Nuestra Senora de Valme Department of Gastroenterology and Hepatology Agencia Sanitaria Costa del Sol University Hospital Cruces Gastroenterology Unit University Hospital Fundacion Alcorcon University Hospital Virgen Macarena University Hospital Virgen de la Arrixaca Hospital of Leon University General Hospital Reina Sofia Department Gastroenterology and Hepatology University Hospital Central de Asturias University Hospital Reina Sofia University Hospital De Gran Canaria Dr. Negrin Hospital San Pedro de Alcantara

AIM:To evaluates the effectiveness and safety of the first generation,NS3/4A protease inhibitors(PIs) in clinical practice against chronic C virus,especially in patients with advanced fibrosis. METHODS:Prospective study and non-experimental analysis of a multicentre cohort of 38 Spanish hospitals that includes patients with chronic hepatitis C genotype 1,treatment-na?ve(TN) or treatment-experienced(TE),who underwent triple therapy with the first generation NS3/4A protease inhibitors,boceprevir(BOC) and telaprevir(TVR),in combination with pegylated interferon and ribavirin. The patients were treatment in routine practice settings. Data on the study population and on adverse clinical and virologic effects were compiled during the treatment period and during follow ***:One thousand and fifty seven patients were included,405(38%) were treated with BOC and 652(62%) with TVR. Of this total,30%(n = 319) were TN and the remaining were TE:28%(n = 298) relapsers,12%(n = 123) partial responders(PR),25%(n = 260) null-responders(NR) and for 5%(n = 57) with prior response unknown. The rate of sustained virologic response(SVR) by intention-to-treatment(ITT) was greater in those treated with TVR(65%) than in those treated with BOC(52%)(P < 0.0001),whereas by modified intention-to-treatment(m ITT) no were found significant differences. By degree of fibrosis,56% of patients were F4 and the highest SVR rates were recorded in the non-F4 patients,both TN and TE. In the analysis by groups,the TN patients treated with TVR by ITT showed a higher SVR(P = 0.005). However,by m ITT there were no significant differences between BOC and TVR. In the multivariate analysis by m ITT,the significant SVR factors were relapsers,IL28 B CC and non-F4; the type of treatment(BOC or TVR) was not significant. The lowest SVR values were presented by the F4-NR patients,treated with BOC(46%) or with TVR(45%). 28% of the patients interrupted the treatment,mainly by non-viral response(51%):this outcome was

关键词： Hepatitis C Boceprevir Telaprevir First-generation protease inhibitors Advanced fibrosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy

引用

World Journal of Clinical Oncology 2018年第2期9卷 33-41页

作者： Marco Galvez Carlos A Castaneda joselyn sanchez Miluska Castillo Lia Pamela Rebaza Gabriela Calderon Miguel De La Cruz jose Manuel Cotrina Julio Abugattas Jorge Dunstan Henry Guerra Omar Mejia Henry L gomez Department of Medical Oncology Instituto Nacional de Enfermedades Neoplasicas Faculty of Medicine Universidad Peruana San Juan Bautista Department of Research Instituto Nacional de Enfermedades Neoplasicas Department of Breast Cancer Surgery Instituto Nacional de Enfermedades Neoplasicas Department of Pathology Instituto Nacional de Enfermedades Neoplasicas

AIM To investigate the survival impact of clinicopathological factors, including pathological complete response(p CR) and tumor-infiltrating lymphocytes(s TIL) levels according to subtypes, in breast cancer(BC) patients who received neo-adjuvant chemotherapy(NAC).METHODS We evaluated 435 BC patients who presented and received NAC at the Instituto Nacional de Enfermedades Neoplasicas from 2003 to 2014. s TIL was analyzed as the proportion of tumor stroma occupied by lymphocytes, and was prospectively evaluated on hematoxylin and eosin-stained sections of the preN AC core biopsy. p CR was considered in the absence of infiltrating cancer cells in primary tumor and axillary lymph nodes. Analysis of statistical association between clinical pathological features, s TIL, p CR and survival were carried out using *** Median age was 49 years(range 24-84 years) and the most frequent clinical stage was ⅢB(58.3%). Luminal A, Luminal B, HER2-enriched and(triple-negative) TN phenotype was found in 24.6%, 37.9%, 17.7% and 19.8%, respectively. p CR was observed in 11% and median percentage of s TIL was 40%(2%-95%) in the whole population. p CR was associated to Ct1-2(P = 0.045) and to high s TIL(P = 0.029) in the whole population. There was a slight trend towards significance for s TIL(P = 0.054) in Luminal A. s TIL was associated with grade Ⅲ(P < 0.001), no-Luminal A subtype(P < 0.001), RE-negative(P < 0.001), PgR-negative(P < 0.001), HER2-positive(P = 0.002) and p CR(P = 0.029) in the whole population. Longer disease-free survival was associated with grade Ⅰ-Ⅱ(P = 0.006), cN 0(P < 0.001), clinical stage Ⅱ(P = 0.004), ER-positive(P < 0.001), Pg R-positive(P < 0.001), luminal A(P < 0.001) and p CR(P = 0.002). Longer disease-free survival was associated with grade Ⅰ-Ⅱ in Luminal A(P < 0.001), N0-1 in Luminal A(P = 0.045) and TNBC(P = 0.01), clinical stage Ⅱ in Luminal A(P = 0.003) and TNBC(P = 0.038), and pC R in TNBC(P < 0.001). Longer overall survival was associated wi

关键词： Breast cancer Subtype Tumor-infiltrating lymphocytes Neoadjuvant therapy Pathological complete response Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current role in facial allograft transplantation:what have we learned?

引用

Plastic and Aesthetic Research 2016年第1期3卷 211-218页

作者： Pedro Infante-Cossio Fernando Barrera-Pulido Tomas gomez-Cia Domingo Sicilia-Castro Alberto Garcia-Perla-Garcia Purificacion Gacto-sanchez jose Maria Hernandez-Guisado Araceli Lagares-Borrego Rocio Narros-Gimenez juan-David Gonzalez-Padilla Department of Oral and Maxillofacial Surgery Virgen del Rocio University Hospital41013 SevilleSpain Department of Plastic and Reconstructive Surgery Virgen del Rocio University Hospital41013 SevilleSpain

Face transplant(FT)has evolved enormously in the last 10 years since the successful completion of the first facial *** procedure has become a new reconstructive option for complex facial deformities to restore the anatomy of patients with severely disfigured *** authors review the literature and discuss the main surgical,immunological,and ethical aspects as well as the results described in patients undergoing *** date there have been more than thirty FT *** main indication was post-traumatic *** all cases a standard immunosuppression was performed with three drugs,although acute rejection episodes were observed,that could be controlled with conventional immunosuppressive ***,functional and aesthetic results have been excellent at short-term and high satisfaction rate exceeded initial expectations,although long-term data are still *** complications were opportunistic *** deaths that occurred have reopened the ethical debate about the potential complications and concerns of providing informed consent to *** progresses in microsurgical techniques and preoperative planning have promoted the evolution from partial to full *** these are on the basis of accurate and careful selection of well-motivated *** next challenge will be getting new immunosuppressive treatment *** clinical experience has demonstrated the FT viability,it is still considered an experimental procedure in which we have much to learn to define its true role in the current reconstructive surgery and resolve major technical,medical and ethical problems involved.

关键词： Face transplantation composite tissue transplantation facial allograft transplantation facial reconstruction outcomes and complications of face transplantation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：